Screener
Gyre Therapeutics, Inc. GYRE Q3 2026 earnings
Reported November 6, 2026
Revenue$32.9MBeat by $4.5M
EPS-$0.04Beat by $0.11
Revenue estimate$28.4M
EPS estimate-$0.15
“I am pleased with our execution in the third quarter, our first full quarter incorporating Cullgen's operations within Gyre Therapeutics. We are advancing our protein degrader pipeline toward first-in-human data and initiating new clinical programs next year. Meanwhile, after recently completing an onsite inspection by China's National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027. Together, these programs are expected to drive our next phase of growth and demonstrate the strength of our unique business model, combining U.S. innovation with capital-efficient operations in China.”
Next report
Date not yet announcedSegments
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Gyre Therapeutics, Inc. report Q3 2026 earnings?
- Gyre Therapeutics, Inc. (GYRE) reported Q3 2026 earnings on November 6, 2026.
- What were Gyre Therapeutics, Inc.'s Q3 2026 revenue and EPS?
- Gyre Therapeutics, Inc. reported revenue of $32.9M and eps of $-0.04 for Q3 2026.
- Did Gyre Therapeutics, Inc. beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $28.4M by $4.5M. EPS beat the consensus estimate of $-0.15 by $0.11.
- How did Gyre Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 7.8% from $30.6M a year earlier.
- Where can I find Gyre Therapeutics, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-449985) and the 10-Q periodic report (0001193125-26-450334) directly on SEC EDGAR. The filing index links above go to sec.gov.
